CHOSA Oncology AB

CHOSA · Nasdaq Stockholm · Healthcare

0.58SEK +6.2%last day

Price as of 1 October 2026

The price over the past year, with dividends: −57.2%

Performance

1 month

−6.5%

1 year

−57.2%

3 years, per year

−16.1%

5 years, per year

−50.1%

Largest fall, 3 years

−99.1%

Below the peak now

−98.9%

Volatility, 1 year

109.3%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

2.6

Dividend yield

0.0%

Return on equity

−33.2%

Net margin

–

Market value

5 m USD

Quality, value and trend

Where CHOSA Oncology stands against every Nordic stock today. 100 is best.

Quality26

Profitability and a sound balance sheet over time. Better than 26% of Nordic stocks.

Value8

The price measured against earnings, assets and cash flow. Better than 8% of Nordic stocks.

Trend6

The price development over the past year. Better than 6% of Nordic stocks.

Combined2

Quality, value and trend together. Better than 2% of Nordic stocks.

About CHOSA Oncology

CHOSA Oncology AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 2 employees.

Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden and USA. It provides Platin-DRP, a multigene mRNA-based algorithm that predicts a patient's response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites. The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 and is based in Malmö, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis